Shots:
- LEO Pharma has reported 16wk. interim data from P-IIIb (ADHAND) trial assessing Adbry monotx. (tralokinumab; 300mg, Q2W) vs PBO for 16wks. in adults with mod. to sev. atopic dermatitis on hands eligible for systemic therapy, followed by a 16wk. open-label phase, where all pts received Adbry
- Trial met its 1EP, with higher proportion of pts achieving an IGA-AHE score of 0/1 at Wk. 16, & key 2EPs, incl. ≥4-point reductions in itch & pain (HESD) as well as ≥75% & ≥90% HECSI improvements; data to be shared at future conference, while final results are expected by 2025 end
- Tralokinumab is a high-affinity, fully human monoclonal antibody that targets & inhibits interleukin-13 (IL-13), which is marketed as Adtralza & Adbry in the US for treating atopic dermatitis
Ref: Businesswire | Image: Leo Pharma| Press Release
Related News:- Gilead and LEO Pharma Join Forces to Develop STAT6 Program for Multiple Inflammatory Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
